There are 1,767 results relating to "Acheter l"
|
Committees
Published:
30 September 2021
Keith Talbot submission of 30 September 2021
Keith Talbot submission of 30 September 2021.
PE1859/L: Retain falconers rights to practice upland falconry .
Last updated:
11 December 2023
UKSI Official Controls etc Regulations 2023 of 6 November 2023
L., Pyrus L., Ribes L., Papaws (papayas) Rubus L., Syzygium fresh or chilled.
Last updated:
19 April 2023
NHS Borders Evidence Pack
Dec-22 111 Jan-23 64 ae decision to treat M Referral to Treatment (RTT) - % 90% patient to be seen and treated within 18 weeks of n ↑ Dec-22 67.9% Jan-23 88.4% al treated within 18 weeks of referral referral. P l Diagnostics (8 key tests) - Number Zero patients waiting longer than 6 weeks for 8 key a ↑ Dec-22 1202 Jan-23 1073 n waiting >6 weeks diagnostic tests oita CAMHS- % treated within 18 weeks of r ↓ 90% patients seen and treated within 18 weeks of referral Nov-22 31.3% Dec-22 30.8% e referral pO A&E 4 Hour Standard - Patients l 95% of patients seen, discharged or transferred within 4 a ↑ discharged or transferred within 4 Dec-22 63.5% Jan-23 64.7% hours u hours nn Delayed Discharges - Patients A ↑ Zero patients delayed in hospital for more than 72 hours Dec-22 33 Jan-23 45 delayed over 72 hours Psychological Therapies - % treated ↓ 90% patient treated within 18 weeks of referral Nov-22 84.1% Dec-22 81.3% within 18 weeks of referral Drug & Alcohol - Treated within 3 ↔ 90% patient treated within 3 weeks of referral Nov-22 100% Dec-22 100% weeks of referral ↑ Sickness Absence Rates Maintain overall sickness absence rates below 4% Dec-22 6.41% Jan-23 6.91% 14 Cancer Waiting Times (please note there is a 1-month lag time for data) Fig. 9 95% of suspicion of cancer cases seen within 62 Days Percentage Mean UCL LCL Standard % 120% 110% 100% 90% 80% 70% 60% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 10 95% of cancer treatment patients treated within 31 Days Percentage Mean UCL LCL Standard % 105% 100% 95% 90% 85% 80% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M 15 Stage of Treatment- Outpatients Waiting Over 12 Weeks Stage of Treatment Target - Outpatients Waiting Over 12 Weeks 12wks Mean UCL LCL 8000 7000 6000 5000 4000 3000 2000 10000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n -1000 c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 11 16 Stage of Treatment- Inpatients Waiting Over 12 Weeks Stage of Treatment Target - Inpatients Waiting Over 12 Weeks 12wks Mean UCL LCL 2500 2000 1500 1000 5000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 12 17 Patients Treated within the 12 weeks Treatment Time Guarantee Patients Treated within the 12 weeks Treatment Time Guarantee 12wks TTG Mean UCL LCL 250 200 150 100 500 -50 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 13 18 18 Weeks Referral to Treatment Combined Pathway Performance 18 Weeks Percentage Referral to Treatment Combined Pathway Performance Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 14 19 Diagnostic Waits Diagnostics Waits over 6 Weeks Number over 6 weeks Mean UCL LCL 2000 1800 1600 1400 1200 1000 800 600 400 2000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 15 20 CAMHS Waiting Times- 18 Week Referral to Treatment 18 Week Referral to Treatment for CAMHS Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 16 21 Psychological Therapies Waiting Times- 18 Week Referral to Treatment 18 Week Referral to Treatment for Pyschological Therapies Percentage Mean UCL LCL Standard % 110% 90% 70% 50% 30% 10% -10% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 3 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 17 22 Delayed Discharges Fig. 18 23 Fig. 19 DDs at Census Delayed over 72 Hours DDs over 72 hours (3 days) Mean UCL LCL 70 60 50 40 30 20 100 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M Fig. 20 Standard Delayed Bed Days Standard Delayed Bed Days Mean UCL LCL 2000 1500 1000 5000 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 8 9 0 1 2 9 0 1 2 3 1 2 2 2 1 1 2 2 2 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n u u u u u c c c c c a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N M M M M M M M M M 24 Drugs & Alcohol 3 Week Drugs and Alcohol Referral to Treatment Percentage Mean UCL LCL Standard % 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 9 0 1 2 9 0 1 2 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r r r r r c c c c c y y y y y v v v v v g g g g g p b p b p b p b p n n n n n n n n n c c c c c u u u u u a a a a p p p p p e e e e e a a a a a o o o o o u u u u u a a a a e e e e e e e e e u u u u u J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S D D D D D A A A A A N N N N N M M M M M M M M M Fig. 21 25 Number of Alcohol Brief Interventions Delivered Trajectory Tolerance 2018/19 2020/21 2019/20 2020/21 2021/22 2022/23 2500 2000 1500 1000 5000 Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Fig. 22 26 Sickness Absence Sickness Absence Percentage below 4% 8% Percentage Mean UCL LCL Standard % 6% 4% 2% 0% … … … … … … … … … - - - - - - - - - 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 0 1 2 8 9 9 0 0 1 1 2 2 3 8 9 0 1 2 8 9 0 1 2 9 0 1 2 3 r r r r y y y y y 1 2 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 2 2 2 a a a a a a a a a - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l l l t t t t t r r r r r c c c c c v v v v v g g g g g p b p b p b p b p b n n n n n n n n n n M M M M c c c c c u u u u u M M M M M p p p p p e e e e e o o o o o u u u u u a a a a a e e e e e e e e e e u u u u u J J J J J J J J J J J J J J J O O O O O A A A A A S F S F S F S F S F D D D D D A A A A A N N N N N Fig. 23 Covid Absence Percentage Percentage Mean UCL LCL 6% 5% 4% 3% 2% 1% 0% -1% 0 1 2 0 1 2 0 1 2 0 1 2 0 1 1 2 2 3 0 1 2 0 1 2 0 1 2 1 2 0 1 2 1 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - l l l t t t r r r r r c c c y y y v v v g g g p b p b p b n n n n n n u u u c c c a a p p p e e e a a a o o o u u u a a a e e e e e e u u u J J J J J J J J J O O O A A A S F S F S F D D D A A A N N N M M M M M Fig. 24 27 Smoking Quits (Please Note: All figures are cumulative.
News
Published:
13 May 2025
Comataidh Taigh an Ròid a’ tadhal air a’ Mhonadh Ruadh gus tuilleadh sgrùdaidh a dhèanamh air Bile na h-Àrainneachd Nàdarra (Alba)
Bha sinn air leth toilichte fàilte a chur air Comataidh nan Cùisean Dùthchail agus nan Eileanan anns a’ Mhonadh Ruadh agus bha sinn taingeil airson na chuir a h-uile duine a bha an làthair ris an tachartas agus a stiùir na cuairtean làraich.
Last updated:
28 October 2022
SPCB 2022 Paper 53
L obbying Register – Fourth Annual Report By Correspondence Reference: SPCB (2022) Paper 53 Executive summary 1.
Last updated:
6 June 2023
Minutes of the meeting held on 16 May 2023
Cross-Party Group on WASPI MAY 16 2023 6pm Minute Present MSPs Katy Clark Beatrice Wishart Invited guests Peter Aldous MP Bryn Davies (Baron Davies of Brixton) Non-MSP Group Members Catriona Melville Susan McKellar Lynne Craighead C Houston L Paterson M Eley W Millar F Brown L Carmichael R Dickson L Welsh Sandra Gibson Pat Whyte Catherine Scott Susan ?
Last updated:
19 January 2022
Advisor Briefings
The main areas of EU legislative activity in 2021 of relevance to this briefing were the environment and climate change as well as animal and human health as well as food safety. 6 Directive (EU) 2019/770 of the European Parliament and of the Council of 20 May 2019 on certain aspects concerning contracts for the supply of digital content and digital services [2019] OJ L 136/1. 7 Directive (EU) 2019/771 of the European Parliament and of the Council of 20 May 2019 on certain aspects concerning contracts for the sale of goods, amending Regulation (EU) 2017/2394 and Directive 2009/22/EC, and repealing Directive 1999/44/EC [2019] OJ L 136/28. 8 Directive (EU) 2019/1023 of the European Parliament and of the Council of 20 June 2019 on preventive restructuring frameworks, on discharge of debt and disqualifications, and on measures to increase the efficiency of procedures concerning restructuring, insolvency and discharge of debt, and amending Directive (EU) 2017/1132 (Directive on restructuring and insolvency) [2019] OJ L 172/18. 9 Directive (EU) 2019/904 of the European Parliament and of the Council of 5 June 2019 on the reduction of the impact of certain plastic products on the environment [2019] OJ L 155/1. 10 Directive (EU) 2019/883 of the European Parliament and of the Council of 17 April 2019 on port reception facilities for the delivery of waste from ships, amending Directive 2010/65/EU and repealing Directive 2000/59/EC [2019] OJ L 151/116. 11 https://eur-lex.europa.eu/statistics/2021/legislative-acts-statistics.html (accessed 2 November 2021). 4 16.
Last updated:
15 May 2024
WASPI CPG MINS 23 APR 24
Cross-Party Group on WASPI 23 April 2024 Minute Present MSPs Katy Clark R Leonard N Bibby Non-MSP Group Members C Houston L Paterson M Eley W Millar F Brown L Carmichael R Dickson C McMillan C Martinez M Dawson A Jackson A Wallis T Jones T Laird A Wenn C Jardine R Meiklejohn L Craighead S McKellar M Martin M Donnelly Sadie ?
Last updated:
5 September 2023
DecisionMaking_DFMToConvener_31Aug23
GGoovveerr nnaannccee • Plan, monitor and continuously improve policy delivery. aanndd PPrroojjeecctt DDeelliivveerryy LLeevveell TTwwoo:: PPrraaccttiittiioonneerr LLeevveell TThhrreeee:: EExxppeerrtt tr epxE : eer hT l eveL 9 Po l i c y Pr o f essi o n St a nda rds r enoitit car P : owT l eveL noitaul avE l ai cre mmoC s metsyS dna yrevil eD ycil oP yrevil eD tcej or P dna ecnanrevoG gni pol eveD : enO l eveL yr evil e D
pdf.
application/pdf.
771012.
Last updated:
5 December 2024
K Waller request for evidence Assisted Dying for Terminally Ill Scotland Bill
For further information, see: Haining, C.M., Willmott, L., Towler, S. and White, B.P., 2023.
